{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:07:12Z","timestamp":1781417232247,"version":"3.54.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Trial Information<\/jats:title>\n                  <jats:p>Click here to access other published clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>The efficacy of second-line treatment for advanced non-small cell lung carcinoma (NSCLC) without a sensitizing driver gene mutation is still unsatisfactory. The combination of apatinib and chemotherapy improved progression-free survival in the second-line therapy of advanced NSCLC without a sensitizing mutation. This study offers a new treatment strategy for second-line treatment of such patients but requires confirmation in a larger multi-institutional trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study explored the efficacy and safety of apatinib combined with single-agent chemotherapy versus single-agent chemotherapy in the second-line treatment of advanced non-small-cell lung carcinoma (NSCLC) without driver mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this double-arm, open label, exploratory clinical study, we enrolled patients with unresectable locally advanced or advanced NSCLC without driver mutations that had progressed following first-line chemotherapy. The subjects were allocated into an experimental group and a control group by 2:1. The experimental group received apatinib combined with four cycles of docetaxel or pemetrexed until disease progression, intolerable toxicity, or discontinuation at the patient' request. The control group only received four cycles of docetaxel or pemetrexed. The primary endpoints were progression-free survival (PFS), and the secondary endpoints were overall survival (OS), disease control rate (DCR), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-seven patients were enrolled. The efficacy of 33 patients was evaluated. The median PFS was 5.47 versus 2.97 months, the DCR was 95% versus 73%, and the objective response rate (ORR) was 27% versus 9% in the experimental versus control group. The OS was still under follow-up. The most common adverse effects included hypertension, hand-foot skin reaction (HFSR), and fatigue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Apatinib combined with single-agent chemotherapy may be a novel option for second-line treatment of advanced NSCLC<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0519","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T14:48:56Z","timestamp":1592059736000},"page":"e1640-e1649","source":"Crossref","is-referenced-by-count":10,"title":["Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial"],"prefix":"10.1093","volume":"25","author":[{"given":"Zongyang","family":"Yu","sequence":"first","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyu","family":"Cai","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwu","family":"Xu","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"He","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuo","family":"Lai","sequence":"additional","affiliation":[{"name":"Affiliated Union Hospital of Fujian Medical University, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Wang","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencui","family":"Kong","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Huang","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Shi","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Shi","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Fujian Medical University, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ni","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwu","family":"Lin","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wu","sequence":"additional","affiliation":[{"name":"The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujin","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian People's Hospital, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"2021122511253421900_onco13409-bib-0001","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0002","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122511253421900_onco13409-bib-0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.JTO.0000268673.95119.c7","article-title":"Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials","volume":"2","author":"Hotta","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2021122511253421900_onco13409-bib-0004","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0005","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122511253421900_onco13409-bib-0006","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0007","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JTO.0000000000000071","article-title":"CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer","volume":"9","author":"Heist","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2021122511253421900_onco13409-bib-0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122511253421900_onco13409-bib-0009","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1200\/JCO.2012.42.6932","article-title":"Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial","volume":"30","author":"Ramlau","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127306","article-title":"The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: A systematic review and meta-analysis","volume":"10","author":"Sheng","year":"2015","journal-title":"PLoS One"},{"key":"2021122511253421900_onco13409-bib-0011","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/cncr.29893","article-title":"Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"2021122511253421900_onco13409-bib-0012","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511253421900_onco13409-bib-0013","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"2021122511253421900_onco13409-bib-0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122511253421900_onco13409-bib-0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0016","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2018.7102","article-title":"Comparative effectiveness of carboplatin\/pemetrexed with versus without bevacizumab for advanced nonsquamous non-small cell lung cancer","volume":"17","author":"Bagley","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511253421900_onco13409-bib-0018","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0019","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.19.01006","article-title":"Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508","volume":"37","author":"Ramalingam","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511253421900_onco13409-bib-0020","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"2021122511253421900_onco13409-bib-0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2018.5526","article-title":"Anlotinib for refractory advanced non-small cell lung cancer in china","volume":"5","author":"Chen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021122511253421900_onco13409-bib-0022","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/annonc\/mdt212","article-title":"A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)","volume":"24","author":"Groen","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122511253421900_onco13409-bib-0023","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.2147\/OTT.S170722","article-title":"Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: Analyses from the phase III LUME-Lung 1 study","volume":"11","author":"Reck","year":"2018","journal-title":"Onco Targets Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/e1640\/41921842\/oncolo_25_11_e1640.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/e1640\/41921842\/oncolo_25_11_e1640.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:28:00Z","timestamp":1640431680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/11\/e1640\/6443090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,7,25]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0519","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,7,25]]}}}